Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

Status Terminated

Clinical Trial Summary

A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00191477
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Terminated
Phase	Phase 3
Start date	January 2004
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00536588` - A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)	Phase 1
Recruiting	`NCT00872495` - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Terminated	`NCT02900248` - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Completed	`NCT00406068` - Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer	Phase 2/Phase 3
Completed	`NCT00077688` - TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium	Phase 2
Completed	`NCT00462488` - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ	Phase 2
Completed	`NCT00001381` - A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder	Phase 1
Terminated	`NCT00050687` - Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies	Phase 1/Phase 2
Completed	`NCT00343356` - Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder	Phase 2
Completed	`NCT01090388` - Bladder Cancer Patient-Reported Outcomes	N/A
Completed	`NCT00141531` - Phase II Trial of EOquin in High-risk Superficial Bladder Cancer	Phase 2
Completed	`NCT00315237` - Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract	Phase 3
Completed	`NCT00491114` - Intravesical Chemotherapy Treatment of Superficial Bladder Cancer	Phase 2
Completed	`NCT00393809` - Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer	Phase 1/Phase 2
Completed	`NCT00101608` - Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium	Phase 2
Recruiting	`NCT05072600` - Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer	Phase 2
Completed	`NCT00963404` - Image-Guided Tumorboost of Bladder Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT00109655` - Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure	Phase 1
Completed	`NCT00188695` - Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide	Phase 1/Phase 2
Active, not recruiting	`NCT00871754` - Molecular Analysis Of Bladder Cancer